UMass Amherst researchers develop nanoparticle vaccine preventing multiple cancers in mice

A novel nanoparticle vaccine has shown promise in preventing melanoma, pancreatic, and triple-negative breast cancers in laboratory mice. The experimental vaccine, utilizing a "super adjuvant" combined with cancer antigens, triggered a robust immune response, leading to significant tumor-free survival rates and preventing metastasis. This platform technology, developed by UMass Amherst researchers, could potentially be adapted for various cancer types and is being pursued by a startup for therapeutic and preventative applications.